Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

被引：0
|
作者：
Gambacorti-Passerini, Carlo
Orlov, Sergey
Zhang, Li
Braiteh, Fadi
Huang, Huiqiang
Esaki, Taito
Horibe, Keizo
Ahn, Jin-Seok
Beck, Joseph T.
Edenfield, William Jeffrey
Shi, Yuankai
Taylor, Matthew
Tamura, Kenji
Van Tine, Brian A.
Wu, Shang-Ju
Paolini, Jolanda
Li, Sherry
Kim, Tae Min
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4128
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Intrathecal treatment trial of rituximab in progressive MS An open-label phase 1b study
    Bergman, Joakim
    Burman, Joachim
    Gilthorpe, Jonathan D.
    Zetterberg, Henrik
    Jiltsova, Elena
    Bergenheim, Tommy
    Svenningsson, Anders
    NEUROLOGY, 2018, 91 (20) : E1893 - E1901
  • [22] A Phase 1b/2 Open-label Clinical Trial to Evaluate the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma
    Mruthyunjaya, Prithvi
    Schefler, Amy C.
    Kim, Ivana K.
    Bergstrom, Christopher
    Demirci, Hakan
    Tsai, Tony
    Bhavsar, Abdhish R.
    Capone, Antonio
    Marr, Brian
    McCannel, Tara A.
    Javid, Cameron
    Hovland, Peter G.
    Seider, Michael I.
    Rich, Cadmus
    Shields, Carol L.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [23] A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis
    Newsome, Scott
    Shoemaker, Thomas
    Tian, Fan
    Fitzgerald, Kate
    Bhargava, Pavan
    Snoops, Sarah
    Cooper, David
    Mammen, Jennifer
    Mowry, Ellen
    Calabresi, Peter
    NEUROLOGY, 2019, 92 (15)
  • [24] A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis
    Newsome, S. D.
    Tian, F.
    Fitzgerald, K. C.
    Bhargava, P.
    Shoemaker, T.
    Snoops, S.
    Cooper, D.
    Mammen, J.
    Mowry, E. M.
    Calabresi, P. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 18 - 18
  • [25] OPTIMIZE-1, AN OPEN-LABEL PHASE 1B/2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAZALIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
    de Coana, Yago Pico
    Smith, Karin Enell
    Falt, Anette
    Flardh, Maria
    Ellmark, Peter
    Cassier, Philippe
    van Laethem, Jean-Luc
    Carlsson, Malin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A567 - A567
  • [26] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
    Camidge, D. Ross
    Bang, Yung-Jue
    Kwak, Eunice L.
    Iafrate, A. John
    Varella-Garcia, Marileila
    Fox, Stephen B.
    Riely, Gregory J.
    Solomon, Benjamin
    Ou, Sai-Hong I.
    Kim, Dong-Wan
    Salgia, Ravi
    Fidias, Panagiotis
    Engelman, Jeffrey A.
    Gandhi, Leena
    Jaenne, Pasi A.
    Costa, Daniel B.
    Shapiro, Geoffrey I.
    LoRusso, Patricia
    Ruffner, Katherine
    Stephenson, Patricia
    Tang, Yiyun
    Wilner, Keith
    Clark, Jeffrey W.
    Shaw, Alice T.
    LANCET ONCOLOGY, 2012, 13 (10): : 1011 - 1019
  • [27] Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.
    Janku, Filip
    Hamilton, Erika P.
    Mathews, Cara Amanda
    Chu, Christina
    Diamond, Jennifer Robinson
    Hays, John L.
    Arend, Rebecca Christian
    Cristofanilli, Massimo
    Jewell, Andrea
    Reichmann, William
    Kuida, Keisuke
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Richardson, Debra L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
    Jiang, Haiping
    Zheng, Yulong
    Qian, Jiong
    Mao, Chenyu
    Xu, Xin
    Li, Ning
    Xiao, Cheng
    Wang, Huan
    Teng, Lisong
    Zhou, Hui
    Wang, Shuyan
    Zhu, Donglei
    Sun, Tao
    Yu, Yingying
    Guo, Wenying
    Xu, Nong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (03) : 857 - 868
  • [29] Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
    Chari, Ajai
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Nahi, Hareth
    Tang, Jie
    Hellemans, Peter
    Tromp, Brenda
    Clemens, Pamela L.
    Farnsworth, Andrew
    San-Miguel, Jesus F.
    Usmani, Saad Z.
    BLOOD, 2018, 132
  • [30] Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
    Haiping Jiang
    Yulong Zheng
    Jiong Qian
    Chenyu Mao
    Xin Xu
    Ning Li
    Cheng Xiao
    Huan Wang
    Lisong Teng
    Hui Zhou
    Shuyan Wang
    Donglei Zhu
    Tao Sun
    Yingying Yu
    Wenying Guo
    Nong Xu
    Cancer Immunology, Immunotherapy, 2021, 70 : 857 - 868
12345